Skip to main content
. 2024 Feb 12;13(2):180. doi: 10.3390/antibiotics13020180

Figure 3.

Figure 3

Impact of the COVID-19 pandemic on antimicrobial consumption. Dedicated wards for COVID-19 patients were opened in ten institutions. The consumption of most antibiotics used for respiratory infections is shown. (A) amoxicillin/clavulanate; (B) ceftriaxone; (C) piperacillin/tazobactam; (D) macrolides (including erythromycin; azithromycin; spiramycin; roxithromycin).